comparemela.com
Home
Live Updates
Editas Medicine to Present Clinical Data from the RUBY Trial of EDIT-301 for the Treatment of Severe Sickle Cell Disease at the EHA 2023 Congress : comparemela.com
Editas Medicine to Present Clinical Data from the RUBY Trial of EDIT-301 for the Treatment of Severe Sickle Cell Disease at the EHA 2023 Congress
Company-sponsored webinar to be announcedCAMBRIDGE, Mass., May 11, 2023 -- Editas Medicine, Inc. , a clinical stage genome editing company, today announced that a scientific abstract detailing... | May 11, 2023
Related Keywords
United States
,
Frankfurt
,
Brandenburg
,
Germany
,
Cambridge
,
Cambridgeshire
,
United Kingdom
,
Baisong Mei
,
Rabi Hanna
,
Harvard University Cas
,
Department Of Pediatric Hematology Oncology
,
European Hematology Association Congress
,
Broad Institute Cas
,
European Hematology Association
,
Nasdaq
,
Editas Medicine Inc
,
Broad Institute
,
Hybrid Congress
,
Senior Vice President
,
Chief Medical Officer
,
Presentation Details
,
Promising Preliminary Safety
,
Efficacy Results
,
Efficient Ascas
,
Pediatric Hematology Oncology
,
Marrow Transplantation
,
Cleveland Clinic Children
,
Editas Medicine
,
Harvard University
,
Nc Stock Exchange
,
News
,
Information
,
Press Release
,
Ebinar
,
O
,
The
,
Bay
,
023
,
Yeditas
,
Linical
,
Stage
,
Enome
,
Editing
,
Oday
,
Nnounced
,
Hat
,
Cientific
,
Bstract Edit Us28106w1036
,
comparemela.com © 2020. All Rights Reserved.